Orforglipron

SEP 8, 2026 · PHASE 3 TRIAL

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

ClinicalTrials.gov

This is a recruiting Phase 3 trial registration with no results posted; it describes planned enrollment and primary outcomes but contains no efficacy or safety data.

SEP 8, 2026 · PHASE 3 TRIAL

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

ClinicalTrials.gov

This is a registry record for a Phase 3 trial still recruiting; no results are reported, making evidence assessment impossible at this stage.

AUG 14, 2026 · PHASE 3 TRIAL

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

ClinicalTrials.gov

This is a clinical trial registry record with no results reported; it describes a planned Phase 3 interventional study that is active but not yet recruiting or has completed enrollment without posted outcomes.

AUG 4, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Foundayo (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of labeling changes for orforglipron (Foundayo); regulatory action without clinical trial data reported.